



MPS Limited

A-1, Tower A, 4th Floor, Windsor IT Park, Sector 125, Noida
Tel: +91 120 4599 750

Ref: MPSL/SE/110/2025-26

Date: 09 February 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot no. C/1,
G Block, Bandra - Kurla Complex, Bandra (East),
Mumbai - 400 051, India

Symbol: MPSLTD

ISIN: INE943D01017

BSE Limited

Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001, India

Scrip Code: 532440

ISIN: INE943D01017

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Completion of the Acquisition of Unbound Medicine, Inc., USA

Ref: • Our letter dated 30 January 2026 - Intimation of execution of Stock Purchase Agreement for acquisition of Unbound Medicine, Inc., USA
• Our letter dated 04 February 2026 - Disclosure regarding funding arrangements for the proposed acquisition

We refer to our earlier intimation dated 30 January 2026, wherein we had informed that MPS North America LLC ("MPS NA LLC"), a wholly-owned subsidiary of MPS Limited ("the Company"), had entered into a Stock Purchase Agreement ("SPA") dated 30 January 2026 for the acquisition of 100% stake in Unbound Medicine, Inc., USA, for a total consideration of USD 16.50 million (subject to customary adjustments), payable in accordance with the terms and conditions set out in the SPA and other definitive transaction documents.

We hereby inform you that, pursuant to the terms of the SPA and upon satisfaction of the customary closing conditions, the transaction has been successfully completed, and MPS NA LLC has paid the consideration due at completion and acquired 100% stake in Unbound Medicine, Inc., USA. Accordingly, Unbound Medicine, Inc., USA has become a wholly-owned step-down subsidiary of MPS Limited with effect from the date of completion.

The details of the acquisition as required to be disclosed under Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, have already been disclosed vide our letter dated 30 January 2026.

This is for your kind information and records.

Thanking you,

Yours Faithfully,
For **MPS Limited**

Raman Sapra
Company Secretary and Compliance Officer

www.mpslimited.com

Registered Office: RR Towers IV, Super A, 16/17, Thiru-Vi-Ka Industrial Estate, Guindy, Chennai-600032-India, Tel: +91 44 49162222 Email: info@mpslimited.com
Corporate Identification Number: L22122TN1970PLC005795